Myriad Genetics, Inc.
MYGN
$3.84
-$0.27-6.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 831.30M | 837.60M | 823.60M | 802.20M | 774.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 831.30M | 837.60M | 823.60M | 802.20M | 774.20M |
| Cost of Revenue | 249.30M | 252.20M | 254.10M | 248.20M | 241.60M |
| Gross Profit | 582.00M | 585.40M | 569.50M | 554.00M | 532.60M |
| SG&A Expenses | 555.70M | 560.60M | 563.30M | 560.30M | 556.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 920.30M | 925.50M | 918.90M | 905.50M | 888.80M |
| Operating Income | -89.00M | -87.90M | -95.30M | -103.30M | -114.60M |
| Income Before Tax | -126.90M | -123.40M | -116.60M | -156.60M | -235.50M |
| Income Tax Expenses | -25.50M | 3.90M | -600.00K | -1.40M | -900.00K |
| Earnings from Continuing Operations | -101.40 | -127.30 | -116.00 | -155.20 | -234.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.40M | -127.30M | -116.00M | -155.20M | -234.60M |
| EBIT | -89.00M | -87.90M | -95.30M | -103.30M | -114.60M |
| EBITDA | -29.10M | -26.70M | -33.80M | -49.00M | -62.10M |
| EPS Basic | -1.12 | -1.40 | -1.30 | -1.81 | -2.82 |
| Normalized Basic EPS | -0.61 | -0.59 | -0.67 | -0.75 | -0.87 |
| EPS Diluted | -1.12 | -1.41 | -1.31 | -1.82 | -2.83 |
| Normalized Diluted EPS | -0.61 | -0.59 | -0.67 | -0.75 | -0.87 |
| Average Basic Shares Outstanding | 364.00M | 362.50M | 357.50M | 348.50M | 339.60M |
| Average Diluted Shares Outstanding | 364.00M | 362.50M | 357.50M | 348.50M | 339.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |